Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer

Breast

Volumn 18, Issue 1, 2009, Pages 66-68

  Farhat, Mirna H ^a   El Saghir, Nagi S ^a   Shamseddine, Ali I ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Bevacizumab; Breast cancer; Resistance; Trastuzumab

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PUNCH BIOPSY; RECURRENT CANCER; SKIN BIOPSY; SKIN METASTASIS; SKIN SURGERY; THORAX WALL; TREATMENT RESPONSE;

EID: 59949090933     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2008.09.007     Document Type: Article

References (15)

1. Otrock Z.K., Makarem J.A., and Shamseddine A.I. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 38 (2007) 258-268
2. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 82 (1990) 4-6
3. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 36 (1995) 127-137
4. Fidler I.J., and Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79 (1994) 185-188
5. de Castro Junior G., Puglisi F., de Azambuja E., El Saghir N.S., and Awada A. Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the "do ut des" paradigm). Crit Rev Oncol Hematol 59 (2006) 40-50
6. Cobleigh M.A., Langmuir V.K., Sledge G.W., Miller K.D., Haney L., Novotny W.F., et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30 5 Suppl. 16 (2003) 117-124
7. Wedam S.B., Low J.A., Yang S.X., Chow C.K., Choyke P., Danforth D., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24 (2006) 769-777
8. Pegram M.D., and Reese D.M. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol 29 Suppl. 11 (2002) 29-37
9. Ramaswamy B., Elias A.D., Kelbick N.T., Dodley A., Morrow M., Hauger M., et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 12 (2006) 3124-3129
10. du Manoir J.M., Francia G., Man S., Mossoba M., Medin J.A., Viloria-Petit A., et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 12 (2006) 904-916
11. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
12. Konecny G.E., Meng Y.G., Untch M., Wang H.J., Bauerfeind I., Epstein M., et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10 (2004) 1706-1716
13. Epstein M., Ayala R., Tchekmedyian N., Borgstrom P., Pegram M., and Slamon D. HER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF). Breast Cancer Res Treat 76 Suppl. 1 (2002) S143
14. Yen L., You X.L., Al Moustafa A.E., Batist G., Hynes N.E., Mader S., et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 19 (2000) 3460-3469
15. Pegram M, Chan D, Dichmann RA, Tan-Chiu E, Yeon C, Durna L, et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor (VEGF) using trastuzumab (T) and bevacizumab (B) as first-line treatment of HER2-amplified breast cancer. In: Presented at the 29th annual San Antonio breast cancer symposium, San Antonio, Texas; December 14-17, 2006.